<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04765956</url>
  </required_header>
  <id_info>
    <org_study_id>DEBuT-LRP</org_study_id>
    <nct_id>NCT04765956</nct_id>
  </id_info>
  <brief_title>Intravascular Identification and Drug-Eluting Balloon Treatment of Vulnerable Lipid-Rich Plaques</brief_title>
  <acronym>DEBuT-LRP</acronym>
  <official_title>Intravascular Identification and Drug-Eluting Balloon Treatment of Vulnerable Lipid-Rich Plaques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Two-thirds of intracoronary thrombi causing acute coronary syndrome (ACS) result&#xD;
      from rupture of lipid-rich plaques (LRP). After treatment of the culprit lesion in ACS&#xD;
      patients, additional LRPs are found in approximately 50% of patients. Near infrared&#xD;
      spectroscopy (NIRS) combined with intracoronary ultrasound (IVUS) can identify these&#xD;
      vulnerable plaques during coronary angiography (CAG) and is able to assess plaque&#xD;
      characteristics and the lipid-core burden index in a 4mm segment (LCBImm4). It is currently&#xD;
      unknown whether treatment of LRPs leads to plaque stabilization, potentially reducing the&#xD;
      number of subsequent ACS. We hypothesize that LRPs can be treated with balloons coated with&#xD;
      an antiproliferative drug (i.e. drug-eluting balloons; DEB) to deliver selective&#xD;
      pharmacotherapeutic treatment to halt the local atherosclerotic process and subsequently&#xD;
      reduce the risk for atherosclerotic events.&#xD;
&#xD;
      Objectives: To determine the change in plaque characteristics of non-culprit LRPs, as&#xD;
      measured with IVUS/NIRS, after treatment with DEB in patients with ACS.&#xD;
&#xD;
      Study design: Prospective single-arm clinical trial&#xD;
&#xD;
      Study population: Patients with non-ST-elevation acute coronary syndromes&#xD;
&#xD;
      Intervention: If a LRP is detected with IVUS/NIRS, it will be treated with DEB. In case&#xD;
      multiple LRPs are detected, only one will be treated.&#xD;
&#xD;
      Main study endpoints: The difference in LCBImm4 between baseline and 9 months of plaques&#xD;
      treated with DEB.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective single-arm clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LCBImm4 difference of DEB-treated LRPs</measure>
    <time_frame>9 months</time_frame>
    <description>The difference in LCBImm4 between baseline and 9 months follow-up of lipid-rich plaques treated with drug-eluting balloon, as measured with near-infrared spectroscopy (NIRS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in lipid-core burden index in a 4 mm segment (LCBImm4) as measured with IVUS + NIRS from baseline to 9 month follow-up in identified additional LRPs that are not treated with DEB.</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of flow-limiting dissections necessitating bail-out stent implantation;</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of periprocedural myocardial infarction;</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of LRP lesion failure (defined as cardiac death, myocardial infarction, or ischemia-driven revascularization related to an identified non-culprit LRP lesion up to one-year follow-up);</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented composite outcomes, defined as all-cause mortality, myocardial infarction, or any repeat revascularization up to one-year follow-up;</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional IVUS + NIRS lesion characteristics: plaque volume</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional IVUS + NIRS lesion characteristics: minimal lumen area</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Drug-eluting balloon treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug-eluting balloon (DEB) treatment of lipid-rich plaque</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-eluting balloon treatment</intervention_name>
    <description>Drug-eluting balloon (DEB) treatment of lipid-rich plaque</description>
    <arm_group_label>Drug-eluting balloon treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has an acute coronary syndrome without ST-segment elevation on the ECG&#xD;
             (NSTE-ACS), including non-ST-elevation myocardial infarction and unstable angina&#xD;
             pectoris, defined according to the Fourth Universal Definition of Myocardial&#xD;
             Infarction.&#xD;
&#xD;
          -  An invasive revascularization strategy for NSTE-ACS with PCI is chosen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Angiographic exclusion criteria:&#xD;
&#xD;
          1. Previous coronary artery bypass-grafting;&#xD;
&#xD;
          2. Presence of a chronic total occlusion;&#xD;
&#xD;
          3. Too many (complex) coronary lesions requiring staged PCI procedure(s);&#xD;
&#xD;
          4. Procedural complication of the index PCI;&#xD;
&#xD;
             - Clinical exclusion criteria:&#xD;
&#xD;
          5. Unstable patients (the presence of cardiogenic shock, need for intubation, need for&#xD;
             inotropes);&#xD;
&#xD;
          6. Patients with ST-segment elevations on the ECG requiring immediate primary PCI;&#xD;
&#xD;
          7. Body weight &gt; 250 kg;&#xD;
&#xD;
          8. Known renal insufficiency (estimated Glomerular Filtration Rate [eGFR] &lt;30&#xD;
             mL/min/1.73m2 or subject on dialysis);&#xD;
&#xD;
          9. Hypersensitivity or allergy to contrast with inability to properly pre-hydrate;&#xD;
&#xD;
         10. Presence of a comorbid condition with a life expectancy of less than one year;&#xD;
&#xD;
         11. Participation in another trial;&#xD;
&#xD;
         12. Subject is belonging to a vulnerable population (per investigator's judgment, e.g.,&#xD;
             subordinate hospital staff) or is unable to read or write.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jose Henriques</last_name>
    <phone>+31205669111</phone>
    <email>j.p.henriques@amsterdamumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna van Veelen</last_name>
    <email>a.vanveelen@amsterdamumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Amsterdam UMC, location AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Henriques</last_name>
      <email>j.p.henriques@amsterdamumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>J.P.S Henriques</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Lipid-rich plaque</keyword>
  <keyword>Non-ST-elevation myocardial infarction</keyword>
  <keyword>Near-infrared spectroscopy</keyword>
  <keyword>Drug-eluting balloon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

